Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

CF breakthrough: kids may ditch daily enzyme pills after modulator treatment

NCT ID NCT07632768

First seen Jun 10, 2026 · Last updated Jun 20, 2026 · Updated 3 times

Summary

This study looked at whether children with cystic fibrosis (CF) who are taking CFTR modulator drugs and have regained normal pancreatic function can safely stop taking pancreatic enzyme replacement therapy (PERT). Seventeen children were followed for six months after stopping enzymes. Researchers monitored their growth, nutrition, and digestive symptoms to see if stopping enzymes caused any problems.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Riley Hospital for Children

    Indianapolis, Indiana, 46202, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

CFTR modulator therapy (ivacaftor, elexacaftor/tezacaftor/ivacaftor, or vanzacaftor/tezacaftor/deutivacaftor)

What this could lead to

If successful, this could show that some children with CF can safely stop taking daily pancreatic enzyme pills, simplifying their treatment and improving quality of life.

What could go wrong

This is a small, completed study with only 17 participants, so results may not apply to everyone. Stopping enzymes could cause nutritional problems or worsen symptoms in some children.

Conditions

The condition(s) this trial relates to.

cystic fibrosis exocrine pancreatic insufficiency pancreas disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.